Anorexia - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Anorexia - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Anorexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Anorexia: Overview
Anorexia nervosa, also called anorexia, is a potentially life-threatening eating disorder that is characterized by self-starvation and excessive weight loss. The disorder is diagnosed when a person weighs at least 15% less than their normal/ideal body weight. Extreme weight loss in people with anorexia nervosa can lead to dangerous health problems and even death. The exact cause of anorexia is not known, but research suggests that a combination of certain personality traits, emotions, and thinking patterns, as well as biological and environmental factors might be responsible.
Identifying anorexia can be challenging. Secrecy, shame, and denial are characteristics of the disorder. As a result, the illness can go undetected for long periods of time. Although there are no lab tests to specifically diagnose anorexia, the doctor might use various diagnostic tests, such as blood tests, to rule out physical illness as the cause of the weight loss, as well as to evaluate the effects of the weight loss on the body's organs.
Goals of treatment include restoring the person to a healthy weight, treating emotional issues such as low self-esteem, correcting distorted thinking patterns, and developing long-term behavioral changes. Treatment most often involves a combination of the following treatment methods: Psychotherapy: This is a type of individual counseling that focuses on changing the thinking (cognitive therapy) and behavior (behavioral therapy) of a person with an eating disorder. Certain antidepressant medications such as selective serotonin reuptake inhibitors (SSRIs) might be used to help control anxiety and depression associated with an eating disorder. Some antidepressants may also help with sleep and stimulate appetite.
Report Highlights
This segment of the Anorexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anorexia Emerging Drugs
It is currently in Phase I/II stage of development for Anorexia and is being developed by Artelo Biosciences.
Further product details are provided in the report..
Anorexia: Therapeutic Assessment
This segment of the report provides insights about the different Anorexia drugs segregated based on following parameters that define the scope of the report, such as:
Anorexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anorexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anorexia drugs.
Anorexia Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Anorexia - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Anorexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Anorexia: Overview
Anorexia nervosa, also called anorexia, is a potentially life-threatening eating disorder that is characterized by self-starvation and excessive weight loss. The disorder is diagnosed when a person weighs at least 15% less than their normal/ideal body weight. Extreme weight loss in people with anorexia nervosa can lead to dangerous health problems and even death. The exact cause of anorexia is not known, but research suggests that a combination of certain personality traits, emotions, and thinking patterns, as well as biological and environmental factors might be responsible.
Identifying anorexia can be challenging. Secrecy, shame, and denial are characteristics of the disorder. As a result, the illness can go undetected for long periods of time. Although there are no lab tests to specifically diagnose anorexia, the doctor might use various diagnostic tests, such as blood tests, to rule out physical illness as the cause of the weight loss, as well as to evaluate the effects of the weight loss on the body's organs.
Goals of treatment include restoring the person to a healthy weight, treating emotional issues such as low self-esteem, correcting distorted thinking patterns, and developing long-term behavioral changes. Treatment most often involves a combination of the following treatment methods: Psychotherapy: This is a type of individual counseling that focuses on changing the thinking (cognitive therapy) and behavior (behavioral therapy) of a person with an eating disorder. Certain antidepressant medications such as selective serotonin reuptake inhibitors (SSRIs) might be used to help control anxiety and depression associated with an eating disorder. Some antidepressants may also help with sleep and stimulate appetite.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Anorexia R&D. The therapies under development are focused on novel approaches for Anorexia.
This segment of the Anorexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anorexia Emerging Drugs
- ART2713: Artelo Biosciences
It is currently in Phase I/II stage of development for Anorexia and is being developed by Artelo Biosciences.
- PF-07258669: Pfizer
Further product details are provided in the report..
Anorexia: Therapeutic Assessment
This segment of the report provides insights about the different Anorexia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Anorexia
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Anorexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anorexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anorexia drugs.
Anorexia Report Insights
- Anorexia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Anorexia drugs?
- How many Anorexia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Anorexia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anorexia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anorexia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Artelo Biosciences
- Serina Therapeutics
- Pfizer
- Echo Pharmaceuticals
- ART2713
- SER-232
- PF-07258669
- Namisol
Introduction
Executive Summary
Anorexia: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anorexia– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anorexia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anorexia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
PF-07258669: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
SER-232: Serina Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Anorexia Key Companies
Anorexia Key Products
Anorexia- Unmet Needs
Anorexia- Market Drivers and Barriers
Anorexia- Future Perspectives and Conclusion
Anorexia Analyst Views
Anorexia Key Companies
Appendix
Executive Summary
Anorexia: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Anorexia– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Anorexia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anorexia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
PF-07258669: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
SER-232: Serina Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Anorexia Key Companies
Anorexia Key Products
Anorexia- Unmet Needs
Anorexia- Market Drivers and Barriers
Anorexia- Future Perspectives and Conclusion
Anorexia Analyst Views
Anorexia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Anorexia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Anorexia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Anorexia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Anorexia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
